Table 5. Tumour response rate (eligible population).
|
No. of patients (%)
|
||
|---|---|---|
| ASA404-CP (n=34) | CP (n=36) | |
| Investigator assessment | ||
| Number of patients available for assessment | 32 (100.0) | 31 (100.0) |
| Partial response (confirmed) | 11 (34.4) | 9 (29.0) |
| Partial response (unconfirmed) | 2 (6.3) | 3 (9.7) |
| Stable disease | 14 (43.8) | 10 (32.3) |
| Progressive disease | 5 (15.6) | 9 (29.0) |
| Independent assessment | ||
| Number of patients available for assessmenta | 32 (100.0) | 27 (100.0) |
| Partial response | 10 (31.3) | 6 (22.2) |
| Stable disease | 21 (65.6) | 19 (70.4) |
| Progressive disease | 1 (3.1) | 2 (7.4) |
ASA404-CP=ASA404 combined with carboplatin and paclitaxel; CP=carboplatin and paclitaxel.
a
Tumour response could not be evaluated in 11 eligible patients by independent assessment due to: patient death before second tumour assessment (n=3); patient withdrawal before second tumour assessment (n=3); disease progression after cycle 1 and no subsequent scans available (n=2); no target lesion present (n=2); or no baseline scan available (n=1).